Evidence synthesis Stronger human signal 8 randomized trials, 8,009 participants
Adjuvant PSK after curative gastric cancer surgery: meta-analysis
Across eight older Japanese trials, adding PSK to postoperative chemotherapy was associated with a modest improvement in overall survival. The result applies to adjunct PSK in those treatment settings, not to Turkey Tail supplements used alone.
- What was studied
- PSK, a proprietary protein-bound polysaccharide preparation derived from cultured Turkey Tail mycelium
- Setting
- Studied with standard care
- Why it ranks here
- The signal comes from pooled randomized trials with clinical survival outcomes, but the studies are older and product-specific.
Limits and cautions
- The trials were conducted in older Japanese postoperative chemotherapy settings.
- PSK is a specific standardized preparation and should not be treated as equivalent to retail Turkey Tail powders or extracts.
- The meta-analysis does not establish PSK as a replacement for surgery or chemotherapy.
PSK is used as an adjunct in Japan. It is not FDA-approved in the United States as a cancer treatment.
Randomized trial Promising, with limits 262 participants
PSK with chemotherapy after gastric cancer surgery: randomized trial
This older Japanese randomized trial reported better five-year disease-free and overall survival when PSK was added to postoperative chemotherapy. It does not test a retail Turkey Tail supplement or stand-alone mushroom treatment.
- What was studied
- Protein-bound PSK added to mitomycin and oral fluorouracil after curative gastrectomy
- Setting
- Studied with standard care
- Why it ranks here
- The trial measured clinical outcomes and used randomization, but it reflects one older regimen and one specific PSK product.
Limits and cautions
- The trial is from 1994 and used an older chemotherapy regimen.
- The intervention was standardized PSK, not ordinary Turkey Tail powder.
- The study evaluated adjunct use after surgery and does not support replacing standard care.
PSK is not FDA-approved in the United States as a cancer treatment.
Randomized trial Early signal 21 participants
Small randomized PSK study after stage III gastric cancer surgery
The PSK group had better reported three-year survival and a change in one immune-cell measure, but only 21 people were studied. The result is interesting and highly uncertain, so it should be treated as an early signal rather than a reliable treatment estimate.
- What was studied
- PSK 3 g/day plus tegafur-uracil after surgery, compared with tegafur-uracil alone
- Setting
- Studied with standard care
- Why it ranks here
- Randomization is a strength, but the sample is far too small for a stable estimate and the result may be exaggerated by chance.
Limits and cautions
- The sample was extremely small, with 10 participants in the PSK group and 11 in the control group.
- A large apparent effect in a very small trial may not replicate.
- The intervention and chemotherapy context do not match ordinary retail Turkey Tail use.
PSK is not FDA-approved in the United States as a cancer treatment.